Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?

Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disorder for which prompt diagnosis and eculizumab treatment is indicated. The time for relapse and patients at risk for relapse after eculizumab discontinuation are unknown. While some authors believe there is no clinical evidence supp...

ver descrição completa

Detalhes bibliográficos
Autores: Rodríguez García, Eva, Barrios Barrera, Clara, Soler, María José
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2017
País:España
Recursos:Universitat Pompeu Fabra
Repositório:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/34580
Acesso em linha:http://hdl.handle.net/10230/34580
http://dx.doi.org/10.1093/ckj/sfx024
Access Level:Acceso aberto
Palavra-chave:Ronyons -- Malalties -- Tractament
Eculizumab
id ES_e20838ef459d8019bf178bfd5e73df20
oai_identifier_str oai:repositori.upf.edu:10230/34580
network_acronym_str ES
network_name_str España
repository_id_str
spelling Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?Rodríguez García, Eva Barrios Barrera, ClaraSoler, María JoséRonyons -- Malalties -- TractamentEculizumabAtypical hemolytic uremic syndrome (aHUS) is a life-threatening disorder for which prompt diagnosis and eculizumab treatment is indicated. The time for relapse and patients at risk for relapse after eculizumab discontinuation are unknown. While some authors believe there is no clinical evidence supporting eculizumab discontinuation, which may be associated with high collateral risks such as loss of renal function, other authors believe that the drug can be safely discontinued with close patient monitoring. In this editorial, we update the pros and cons for eculizumab discontinuation in aHUS.Oxford University Press201820182017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/34580http://dx.doi.org/10.1093/ckj/sfx024reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésClinical Kidney Journal. 2017 Jun;10(3):320-2© The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.comhttp://creativecommons.org/licenses/by-nc/4.0info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/345802026-06-12T07:21:37Z
dc.title.none.fl_str_mv Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?
title Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?
spellingShingle Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?
Rodríguez García, Eva
Ronyons -- Malalties -- Tractament
Eculizumab
title_short Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?
title_full Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?
title_fullStr Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?
title_full_unstemmed Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?
title_sort Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?
dc.creator.none.fl_str_mv Rodríguez García, Eva
Barrios Barrera, Clara
Soler, María José
author Rodríguez García, Eva
author_facet Rodríguez García, Eva
Barrios Barrera, Clara
Soler, María José
author_role author
author2 Barrios Barrera, Clara
Soler, María José
author2_role author
author
dc.subject.none.fl_str_mv Ronyons -- Malalties -- Tractament
Eculizumab
topic Ronyons -- Malalties -- Tractament
Eculizumab
description Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disorder for which prompt diagnosis and eculizumab treatment is indicated. The time for relapse and patients at risk for relapse after eculizumab discontinuation are unknown. While some authors believe there is no clinical evidence supporting eculizumab discontinuation, which may be associated with high collateral risks such as loss of renal function, other authors believe that the drug can be safely discontinued with close patient monitoring. In this editorial, we update the pros and cons for eculizumab discontinuation in aHUS.
publishDate 2017
dc.date.none.fl_str_mv 2017
2018
2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/34580
http://dx.doi.org/10.1093/ckj/sfx024
url http://hdl.handle.net/10230/34580
http://dx.doi.org/10.1093/ckj/sfx024
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Clinical Kidney Journal. 2017 Jun;10(3):320-2
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by-nc/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Oxford University Press
publisher.none.fl_str_mv Oxford University Press
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422348268994560
score 15,812455

Registros relacionados